Report overview
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule.
This report aims to provide a comprehensive presentation of the global market for Erythropoietin Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Erythropoietin Drugs. This report contains market size and forecasts of Erythropoietin Drugs in global, including the following market information:
Global Erythropoietin Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Erythropoietin Drugs Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Erythropoietin Drugs companies in 2022 (%)
The global Erythropoietin Drugs market was valued at US$ 9422.9 million in 2022 and is projected to reach US$ 13650 million by 2029, at a CAGR of 5.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The retail pharmacies segment dominated the erythropoietin drugs market and accounted for a major part of the overall market share. The ability of retail pharmacies to provide a large customer base for biosimilars coupled with the requirement from anemic patients for EPO drugs as a maintenance therapy is the key contributor to the dominance of this segment in the global market.
We surveyed the Erythropoietin Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Erythropoietin Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Erythropoietin Drugs Market Segment Percentages, by Type, 2022 (%)
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Global Erythropoietin Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Erythropoietin Drugs Market Segment Percentages, by Application, 2022 (%)
Anemia
Kidney Disorders
Other
Global Erythropoietin Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Erythropoietin Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Erythropoietin Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Erythropoietin Drugs revenues share in global market, 2022 (%)
Key companies Erythropoietin Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Erythropoietin Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Erythropoietin Drugs, market overview.
Chapter 2: Global Erythropoietin Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Erythropoietin Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Erythropoietin Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Erythropoietin Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
